|Description||SNS-032, also known as BMS-387032, is a 2-aminothiazole-derived, small-molecule cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. CDK inhibitor SNS-032 selectively binds to CDKs 2, 7, and 9, preventing their phosphorylation and activation; inhibition of CDK activity may result in cell cycle arrest, the induction of apoptosis and decreased tumor cell proliferation in susceptible tumor cell populations. This agent has been shown to sensitize radioresistant tumor cells to ionizing radiation.|
|Appearance||white solid powder|
|Synonyms||BMS-387032; SNS-032; BMS 387032; SNS 032; BMS387032; SNS032|
CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation preve...
Dinaciclib, also known as SCH727965, is a potent CDK inhibitor with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases ...
QS-1189 is a reversible, high selective, orally available cyclin-dependent kinase 7 (CDK7) inhibitor developed for cancer therapy. QS-1189 exhibits antitumor ac...
RGB-286638 is a novel CDK inhibitor. It inhibited several tyrosine and serine/threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1. It demonstrated eq...
Arcyriaflavin A is a potent dual target agent of calcium/calmodulin-dependent protein kinase II (CaMKII) and cyclin-dependent kinase 4 (CDK4). Its IC50 values a...
THZ1-R, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor but has instability in vivo.
LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.LDC000067 reduces Ser2-P, induces p...
WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i...